Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis. The company also provides Jevtana, a taxane derivative for prostate cancer; Taxotere, a taxoid for cancers; Eloxatin, an agent for colorectal cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil, a hematopoietic stem cell mobilizer; and Zaltrap, a protein for metastatic colorectal cancer.
Read More…
Industry, Sector and Symbol
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+33-1-53774000
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableOptionable
Sanofi (EPA:SAN) Frequently Asked Questions
What is Sanofi's stock symbol?
Sanofi trades on the EPA under the ticker symbol "SAN."
What price target have analysts set for SAN?
15 equities research analysts have issued twelve-month target prices for Sanofi's stock. Their forecasts range from €79.00 to €100.00. On average, they anticipate Sanofi's share price to reach €88.80 in the next year. This suggests a possible upside of 7.4% from the stock's current price. View Analyst Price Targets for Sanofi.
What is the consensus analysts' recommendation for Sanofi?
15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sanofi in the last year. There are currently 4 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sanofi.
Has Sanofi been receiving favorable news coverage?
Press coverage about SAN stock has trended somewhat positive recently, according to InfoTrie. The research firm rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Sanofi earned a news sentiment score of 1.8 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Sanofi.
Who are some of Sanofi's key competitors?
What other stocks do shareholders of Sanofi own?
Who are Sanofi's key executives?
Sanofi's management team includes the folowing people:
- Mr. Olivier Brandicourt, CEO & Director (Age 63)
- Mr. Jean-Baptiste Chasseloup de Chatillon, Exec. VP & CFO (Age 54)
- Mr. Laurent Gilhodes, Principal Accounting Officer and VP of Corp. Accounting
- Mr. Bruno Ménard, Chief Information officer
- Mr. George Grofik, Head of Investor Relations
What is Sanofi's stock price today?
One share of SAN stock can currently be purchased for approximately €82.68.
What is Sanofi's official website?
How can I contact Sanofi?
Sanofi's mailing address is 54 rue la Boetie, PARIS, 75008, France. The company can be reached via phone at +33-1-53774000.
MarketBeat Community Rating for Sanofi (EPA SAN)
MarketBeat's community ratings are surveys of what our community members think about Sanofi and other stocks. Vote "Outperform" if you believe SAN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SAN will underperform the S&P 500 over the long term. You may vote once every thirty days.
